SCHEMBL1380448

SCHEMBL1380448

Cc1noc(C)c1S(=O)(=O)Nc1cc2ccccc2c(N2CCN(C)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
TSHR P16473 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPK1 P28482 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
ALDH1A1 P00352 6/20 0.48
POLB P06746 3/20 0.48
GFER P55789 1/20 0.46
HTT P42858 4/20 0.43
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
PKM P14618 3/20 0.42
AKT1 P31749 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383478 0.83 HTR3A (0.44) LMNACYP1A2CYP2D6ALDH1A1HTT
SCHEMBL1381190 0.81 HTR3A (0.51) LMNACYP1A2CYP2D6ALDH1A1HPGD
SCHEMBL1380690 0.80 GBA1 (0.51) LMNACYP1A2CYP2D6ALDH1A1HTT
SCHEMBL3623707 0.78 HTR6 (0.46) CYP1A2CYP2D6ALDH1A1HPGDHTR3E
SCHEMBL1379060 0.77 HTR6 (0.47) LMNATSHRCYP1A2CYP2D6MAPK1
Hydrochloric Acid SCHEMBL1380936 0.77 HTR6 (0.45) CYP1A2CYP2D6ALDH1A1HPGDHTR3E
SCHEMBL3626281 0.76 HSD11B1 (0.50) CYP1A2CYP2D6ALDH1A1HTR3EHTR3B
SCHEMBL1379933 0.76 SCN9A (0.47) LMNAMAPK1ALDH1A1HPGDKMT2A
Hydrochloric Acid SCHEMBL1380788 0.75 HSD11B1 (0.49) CYP1A2CYP2D6ALDH1A1HTR3EHTR3B
SCHEMBL1378323 0.75 ALDH1A1 (0.49) LMNATSHRCYP1A2CYP2D6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4731114-B2 2011-07-20 JP claimed
US-20070066599-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2007-03-22 US claimed
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 EP claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066599-A1 New compounds SULT2A1, GPR119, STS LMNA 3860/4885TSHR 1178/4885CYP1A2 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.